Loading…
In Vitro Anti‐Toxoplasma gondii Activity Evaluation of a New Series of Quinazolin‐4(3H)‐one Derivatives
Toxoplasmosis post serious threaten to human health, leading to severely eye and brain disease, especially for immunocompromised patients and pregnant women. The multiple side effects and long dosing period of current main treatment regiments calls for high effective and low toxicity anti‐toxoplasmo...
Saved in:
Published in: | Chemistry & biodiversity 2021-12, Vol.18 (12), p.e2100687-n/a |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Toxoplasmosis post serious threaten to human health, leading to severely eye and brain disease, especially for immunocompromised patients and pregnant women. The multiple side effects and long dosing period of current main treatment regiments calls for high effective and low toxicity anti‐toxoplasmosis drugs. Herein, we report our efforts to synthesize a series of 2‐(piperazin‐1‐yl)quinazolin‐4(3H)‐one derivatives and investigate their activity against Toxoplasma gondii tachyzoites in vitro based on cell phenotype screening. Among the 26 compounds, 8w and 8x with diaryl ether moiety at the side chain of piperazine exhibited good efficacy to inhibit T. gondii, with IC50 values of 4 μM and 3 μM, respectively. Structure‐activity relationship (SAR) studies implies that hydrophobic aryl at the side chain would be preferred for improvement of activity. Molecular docking study reveals these two compounds appeared high affinity to TgCDPK1 by interaction with the hydrophobic pocket of ATP‐binding cleft. |
---|---|
ISSN: | 1612-1872 1612-1880 |
DOI: | 10.1002/cbdv.202100687 |